avapro and pioglitazone
avapro has been researched along with pioglitazone in 11 studies
Research
Studies (11)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 3 (27.27) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Gust, R; Obexer, P; Salcher, S; Schoepf, AM | 1 |
| Norman, BH | 1 |
| Clemenz, M; Gineste, R; Helleboid, S; Hennuyer, N; Janke, J; Kintscher, U; Ruiz, P; Schupp, M; Staels, B; Unger, T; Witt, H | 1 |
| Boschmann, M; Engeli, S; Gorzelniak, K; Janke, J; Jordan, J; Luft, FC; Nystrom, FH; Sauma, L; Schupp, M; Sharma, AM | 1 |
| Jin, D; Miyazaki, M; Takai, S | 1 |
| Abdelhafez, AT; Ahmed, AM; Ahmed, MA; Gomaa, AMS; Sayed, MM | 1 |
Reviews
2 review(s) available for avapro and pioglitazone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies.
Topics: Animals; Cell Line; Cell Survival; Chemical and Drug Induced Liver Injury; Drug Discovery; Drug Evaluation, Preclinical; Hepatocytes; Humans; Liver; Mitochondria, Liver; Pharmaceutical Preparations; Risk Assessment; Tissue Distribution | 2020 |
Other Studies
9 other study(ies) available for avapro and pioglitazone
| Article | Year |
|---|---|
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
Topics: Animals; Cell Death; Cell Proliferation; Chlorocebus aethiops; COS Cells; Drug Design; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; PPAR gamma; Structure-Activity Relationship; Telmisartan | 2020 |
Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity.
Topics: 3T3 Cells; Acrylates; Adipocytes; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Benzoates; Biphenyl Compounds; Cell Differentiation; Chlorocebus aethiops; COS Cells; Gene Expression Regulation; Imidazoles; Irbesartan; Mice; Pioglitazone; PPAR gamma; Protein Conformation; Telmisartan; Tetrazoles; Thiazolidinediones; Thiophenes | 2005 |
Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-gamma activation.
Topics: Adipogenesis; Adiponectin; Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Humans; Irbesartan; Lipoprotein Lipase; Losartan; Luciferases; Male; Pioglitazone; PPAR gamma; Receptor, Angiotensin, Type 1; RNA, Messenger; Telmisartan; Tetrazoles; Thiazolidinediones | 2006 |
Irbesartan prevents metabolic syndrome in rats via activation of peroxisome proliferator-activated receptor γ.
Topics: Adiponectin; Adipose Tissue; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Gene Expression Regulation; Glucose Transporter Type 4; Hypertension; Hypertriglyceridemia; Hypoglycemic Agents; Insulin Resistance; Irbesartan; Male; Metabolic Syndrome; Pioglitazone; PPAR gamma; Rats; Rats, Inbred SHR; RNA, Messenger; Tetrazoles; Thiazolidinediones; Valine; Valsartan | 2011 |
Pioglitazone and/or irbesartan ameliorate COPD-induced endothelial dysfunction in side stream cigarette smoke-exposed mice model.
Topics: Animals; Antihypertensive Agents; Cigarette Smoking; Disease Models, Animal; Endothelium; Hypoglycemic Agents; Irbesartan; Lung; Male; Mice; Pioglitazone; Pulmonary Disease, Chronic Obstructive; Smoke | 2021 |